Want to see FR:ABVX full AI Analyst Report?
ABVX Stock Chart & Stats
€99.95
-€1.20(-1.06%)
At close: 4:00 PM EDT
€99.95
-€1.20(-1.06%)
Day’s Range― - ―
52-Week Range€60.45 - €139.00
Previous CloseN/A
Volume27.27K
Average Volume (3M)153.59K
Market Cap
€6.91B
Enterprise Value€8.80B
Total Cash (Recent Filing)€410.68M
Total Debt (Recent Filing)€1.21M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Dec 14, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.71
Shares Outstanding87,530,370
10 Day Avg. Volume120,115
30 Day Avg. Volume153,591
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€132.00Price Target Upside32.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.69
Revenue Forecast (FY)€3.96M
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetThe 2025 balance-sheet improvement provides greater financial flexibility than in prior years, with low leverage and a larger equity base. This can help Abivax continue funding development and operations, although it does not eliminate the need to manage ongoing cash consumption.
Focused Clinical PipelineA focused therapeutic strategy can concentrate research resources and clinical expertise around chronic inflammatory diseases. Obefazimod gives the company a defined lead program and the potential to address multiple related indications if development and regulatory objectives are achieved.
Historically Strong Gross MarginNear-100% historical gross margins indicate that the underlying economics of recorded revenue were favorable when commercial or other revenue was present. If meaningful revenue returns, this margin profile could provide substantial contribution toward research, development, and corporate costs.
Bears Say
Deepening LossesPersistent and widening net and operating losses show that the current business remains far from profitability. Continued losses can consume the resources needed for clinical development and increase dependence on financing, making future earnings power highly dependent on successful execution and commercialization.
Unstable Revenue BaseA revenue base that dropped to zero in 2025 provides little evidence of recurring commercial traction or self-sustaining operations. This volatility makes planning and investment funding more difficult, while leaving the company reliant on pipeline progress rather than established product revenue.
Persistent Cash BurnSustained negative operating and free cash flow means Abivax is not currently funding research and operations from internally generated cash. The roughly -162M 2025 free-cash-flow figure reinforces the need for external financing and creates ongoing pressure on financial runway.
Abivax SA News
ABVX FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest stock price was €60.45 and its highest was €139.00 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €6.91B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is Dec 14, 2026 which is in 63 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on Sep 21, 2026. The company reported -€1.47 earnings per share for the quarter, missing the consensus estimate of -€0.801 by -€0.669.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Undervalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.87.
How many shares outstanding does Abivax SA have?
Abivax SA has 87,530,370 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€1.47 in its last earnings report, missing expectations of -€0.801. Following the earnings report the stock price went down -4.688%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in FR:ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
ABVX Stock 12 Month Forecast
Average Price Target
€132.00
▲(32.07% Upside)